Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Effectiveness and safety of antiviral or antibody treatments for coronavirus

Patricia Rios, Amruta Radhakrishnan, Jesmin Antony, Sonia Thomas, Matthew Muller, Sharon E. Straus, Andrea C. Tricco
doi: https://doi.org/10.1101/2020.03.19.20039008
Patricia Rios
Knowledge Translation Program, Li Ka Shing Knowledge Institute, St. Michael’s Hospital
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Amruta Radhakrishnan
Knowledge Translation Program, Li Ka Shing Knowledge Institute, St. Michael’s Hospital
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jesmin Antony
Knowledge Translation Program, Li Ka Shing Knowledge Institute, St. Michael’s Hospital
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sonia Thomas
Knowledge Translation Program, Li Ka Shing Knowledge Institute, St. Michael’s Hospital
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Matthew Muller
Knowledge Translation Program, Li Ka Shing Knowledge Institute, St. Michael’s Hospital
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sharon E. Straus
Knowledge Translation Program, Li Ka Shing Knowledge Institute, St. Michael’s Hospital
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Andrea C. Tricco
Knowledge Translation Program, Li Ka Shing Knowledge Institute, St. Michael’s Hospital
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: Andrea.Tricco@unityhealth.to
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

ABSTRACT

Background To identify safe and effective medical countermeasures (e.g., antivirals/antibodies) to address the current outbreak of a novel coronavirus (COVID-19)

Methods Comprehensive literature searches were developed by an experienced librarian for MEDLINE, EMBASE, the Cochrane Library, and biorxiv.org/medrxiv.org; additional searches for ongoing trials and unpublished studies were conducted in clinicaltrials.gov and the Global Infectious Diseases and Epidemiology Network (GIDEON). Title/abstract and full-text screening, data abstraction, and risk of bias appraisal were carried out by single reviewers.

Results 54 studies were included in the review: three controlled trials, 10 cohort studies, seven retrospective medical record/database studies, and 34 case reports or series. These studies included patients with severe acute respiratory syndrome (SARs, n=33), middle east respiratory syndrome (MERS, n=16), COVID-19 (n=3), and unspecified coronavirus (n=2). The most common treatment was ribavirin (n=41), followed by oseltamivir (n=10) and the combination of lopinavir/ritonavir (n=7). Additional therapies included broad spectrum antibiotics (n=30), steroids (n=39) or various interferons (n=12). No eligible studies examining monoclonal antibodies for COVID-19 were identified. One trial found that ribavirin prophylactic treatment statistically significantly reduced risk of MERS infection in people who had been exposed to the virus. Of the 21 studies reporting rates of ICU admission in hospitalized SARS or MERS patients, none reported statistically significant results in favour of or against antiviral therapies. Of the 40 studies reporting mortality rates in hospitalized SARS or MERS patients, one cohort study (MERS) and one retrospective study (SARS) found a statistically significant increase in the mortality rate for patients treated with ribavirin. Eighteen studies reported potential drug-related adverse effects including gastrointestinal symptoms, anemia, and altered liver function in patients receiving ribavirin.

Conclusion The current evidence for the effectiveness and safety of antiviral therapies for coronavirus is inconclusive and suffers from a lack of well-designed prospective trials or observational studies, preventing any treatment recommendations from being made. However, it is clear that the existing body of evidence is weighted heavily towards ribavirin (41/54 studies), which has not shown conclusive evidence of effectiveness and may cause harmful adverse events so future investigations may consider focusing on other candidates for antiviral therapy.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

TBD

Author Declarations

All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.

Yes

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Footnotes

  • Copyright claims/Disclaimers The intellectual property rights in data and results generated from the work reported in this document are held in joint ownership between the MAGIC team and the named Contributors.

  • Users are permitted to disseminate the data and results presented in this report provided that the dissemination (i) does not misrepresent the data, results, analyses or conclusions, and (ii) is consistent with academic practice, the rights of any third party publisher, and applicable laws. Any dissemination of the data and results from this document shall properly acknowledge the MAGIC team and named Contributors.

Data Availability

All datasets supporting the conclusions of this article are included within the article.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Back to top
PreviousNext
Posted March 23, 2020.
Download PDF
Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Effectiveness and safety of antiviral or antibody treatments for coronavirus
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Effectiveness and safety of antiviral or antibody treatments for coronavirus
Patricia Rios, Amruta Radhakrishnan, Jesmin Antony, Sonia Thomas, Matthew Muller, Sharon E. Straus, Andrea C. Tricco
medRxiv 2020.03.19.20039008; doi: https://doi.org/10.1101/2020.03.19.20039008
Reddit logo Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
Effectiveness and safety of antiviral or antibody treatments for coronavirus
Patricia Rios, Amruta Radhakrishnan, Jesmin Antony, Sonia Thomas, Matthew Muller, Sharon E. Straus, Andrea C. Tricco
medRxiv 2020.03.19.20039008; doi: https://doi.org/10.1101/2020.03.19.20039008

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Infectious Diseases (except HIV/AIDS)
Subject Areas
All Articles
  • Addiction Medicine (271)
  • Allergy and Immunology (559)
  • Anesthesia (135)
  • Cardiovascular Medicine (1778)
  • Dentistry and Oral Medicine (240)
  • Dermatology (173)
  • Emergency Medicine (317)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (662)
  • Epidemiology (10834)
  • Forensic Medicine (8)
  • Gastroenterology (595)
  • Genetic and Genomic Medicine (2968)
  • Geriatric Medicine (289)
  • Health Economics (534)
  • Health Informatics (1938)
  • Health Policy (837)
  • Health Systems and Quality Improvement (747)
  • Hematology (295)
  • HIV/AIDS (634)
  • Infectious Diseases (except HIV/AIDS) (12535)
  • Intensive Care and Critical Care Medicine (697)
  • Medical Education (300)
  • Medical Ethics (89)
  • Nephrology (325)
  • Neurology (2819)
  • Nursing (152)
  • Nutrition (435)
  • Obstetrics and Gynecology (560)
  • Occupational and Environmental Health (600)
  • Oncology (1475)
  • Ophthalmology (444)
  • Orthopedics (172)
  • Otolaryngology (259)
  • Pain Medicine (190)
  • Palliative Medicine (56)
  • Pathology (382)
  • Pediatrics (870)
  • Pharmacology and Therapeutics (368)
  • Primary Care Research (341)
  • Psychiatry and Clinical Psychology (2653)
  • Public and Global Health (5393)
  • Radiology and Imaging (1019)
  • Rehabilitation Medicine and Physical Therapy (599)
  • Respiratory Medicine (729)
  • Rheumatology (330)
  • Sexual and Reproductive Health (294)
  • Sports Medicine (280)
  • Surgery (329)
  • Toxicology (48)
  • Transplantation (151)
  • Urology (127)